Quick Takeaways
- GOLDMAN SACHS GROUP INC filed SCHEDULE 13G/A for SYNDAX PHARMACEUTICALS, INC. Common Stock (SNDX).
- Disclosed ownership: 6.5%.
- Date of event: 30 Jun 2025.
GOLDMAN SACHS GROUP INC - 30 Jun 2025 SCHEDULE 13G/A Report for SYNDAX PHARMACEUTICALS, INC. Common Stock (SNDX)
- Filing Manager
- GOLDMAN SACHS GROUP INC
- Reporting Manager
- THE GOLDMAN SACHS GROUP, INC.
- Symbol
- SNDX
- Shares outstanding
- 85,874,278 shares
- Disclosed Ownership
- 5,581,828 shares
- Ownership
- 6.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Aug 2025, 17:52:51 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 09 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GOLDMAN SACHS GROUP INC disclosed 6.5% ownership in SYNDAX PHARMACEUTICALS, INC. Common Stock (SNDX) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 09 May 2025.
- Current filing was accepted on 13 Aug 2025, 17:52.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | 6.5% | 5,581,828 | 0 | 5,581,718 | Name: | Attorney-in-fact | |
| GOLDMAN SACHS & CO. LLC | 6.5% | 5,581,828 | 0 | 5,581,718 | Name: | Attorney-in-fact |